JNJ Stock Chart & Stats
$4609.99
$90.99(2.01%)
At close: 4:00 PM EDT
$4609.99
$90.99(2.01%)
Day’s Range― - ―
52-Week Range$3,150.00 - $4,725.00
Previous CloseN/A
Volume77.00
Average Volume (3M)243.00
Market Cap
$10.72T
Enterprise Value$649.67K
Total Cash (Recent Filing)$20.76B
Total Debt (Recent Filing)$49.04B
Price to Earnings (P/E)29.6
Beta-0.28
Next Earnings
Oct 20, 2026EPS Estimate
52.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.65
Shares Outstanding2,409,898,700
10 Day Avg. Volume112
30 Day Avg. Volume243
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,890.50Price Target Upside6.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)202.15
Revenue Forecast (FY)$1.76T
Bulls Say, Bears Say
Bulls Say
High And Durable Profitability MarginsJohnson & Johnson reports very high trailing‑twelve‑month margins across the P&L, supporting resilient operating cash generation and reinvestment capacity. Strong gross and operating margins provide structural buffer versus pricing and cost shocks and fund R&D and launches without heavy leverage.
Robust Free Cash Flow And Cash BufferFCF converts a high share of reported earnings into cash and the company holds a sizable ~$21B cash/securities balance. Durable cash generation supports funding of launches, M&A, and settlements while retaining balance sheet flexibility to invest in pipeline and return capital through cycles.
Diversified, High‑growth Innovative Medicine PortfolioMultiple brands and recent launches are delivering high double‑digit growth, reducing reliance on any single legacy product. Broad pipeline momentum and successful new launches (ICOTYDE, INLEXZO) create durable revenue tailwinds and support margin sustainability as older franchise pressure persists.
Bears Say
STELARA Biosimilar‑driven Revenue LossA steep, biosimilar‑driven decline in a legacy immunology franchise represents structural erosion rather than a short blip. Material base revenue loss forces J&J to replace significant dollars via new launches and pricing, increasing execution risk and pressuring consolidated growth until newer products scale fully.
MedTech Procedure And Competitive PressuresMedTech exposure to procedure volumes, physician behavior and regional inventory cycles has created persistent headwinds in cardiovascular and certain devices. Competitive PFA dynamics and slower procedure recovery compress near‑term growth visibility and can weigh on device margins and capital equipment replacement cycles.
Acquisition And Collaboration Near‑term EPS DilutionStrategic deals expand oncology and novel modality exposure but impose a material near‑term hit: in‑process R&D charges and projected EPS dilution in 2026–27. These transactions raise short‑term profitability pressure and increase execution risk on realizing future pipeline returns and milestone‑dependent payments.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $3150.00 and its highest was $4725.00 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $10.72T.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Oct 20, 2026 which is in 79 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jul 15, 2026. The company reported $50.308 earnings per share for the quarter, beating the consensus estimate of $49.527 by $0.781.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson does not currently pay dividends.
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 52.41.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,898,700 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $50.308 in its last earnings report, beating expectations of $49.527. Following the earnings report the stock price went down -2.921%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in MX:JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4,890.50 (6.08% Upside)
$4,890.50 (6.08% Upside)
Blogger Sentiment
Bullish
MX:JNJ Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $143.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.31%
12-Months-Change
Fundamentals
Return on Equity
2.04%
Trailing 12-Months
Asset Growth
3.97%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
JNJ Company Deck
JNJ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company reported solid top‑line growth, strong performance from a broad set of Innovative Medicine launches (many products delivering high double‑digit growth), successful new product launches (ICOTYDE, INLEXZO), raised guidance for full‑year sales and EPS, and improved operating margin expectations. Headwinds exist — notably STELARA's steep decline, MedTech pressure in cardiovascular/Abiomed, regional inventory impacts (China), higher other expenses and a higher GAAP tax rate — but management characterized these as addressable and emphasized diversified, multi‑product strength, cash flow recovery, and upcoming pipeline and regulatory catalysts.View all MX:JNJ earnings summariesJNJ Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$4,890.50
▲(6.08% Upside)